Abstract
Background: The pivotal Phase III immunogenicity study of the 9vHPV vaccine in girls and boys (age 9-15 years) was extended to assess long-term immunogenicity and effectiveness through 10 years post-dose 3. We describe the first interim analysis at month 72. Subsequent analyses are planned at months 96 and 126, respectively. Methods: Overall, 1272 subjects (971 females, 301 males) …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
